Progress on Development of RNA Base Editing Technologies for Precision Medicines, including Axiomer® platform presented at TIDES EU by Gerard Platenburg - ProQR Therapeutics
… Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive … and development and is currently in charge of our Innovation unit. Antisense oligonucleotides (AONs) have …
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… platform for the exchange and sharing of insights and innovations to drive the future of clinical development in … platform for the exchange and sharing of insights and innovations to drive the future of clinical development in …
… Unlocking the Potential of Innovative Editing Oligonucleotides to Address Liver … Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive … and development and is currently in charge of our Innovation unit. Axiomer ® , an RNA editing platform, uses …
ProQR recognizes the importance of advancing diversity, equity, and inclusivity (DEI) in the workplace to inspire each employee to fully thrive and to make their maximum contribution to ProQR.
… of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our … of our collaboration with Lilly . Lilly is a leader in innovative RNA science, making them a great partner for our … developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration. Andrew C. …
